Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG002C0106 in Healthy Adults
NCT06494527Phase 1Completed
- Sponsor
- Rigerna Therapeutics
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing RG002C0106 with Placebo (2 arms). Primary endpoint: Incidence of adverse events and serious adverse events related to the investigational drug up to 169 days. Started Oct 2024; status: completed.
02
Drugs
RG002C0106
Beyond the preview
Go deeper on NCT06494527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494527.